Clinical trials: Tenecteplase
Stroke
Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China
The ORIENTAL study is a prospective, multicenter, continuously enrolled real-world cohort designed to evaluate the effectiveness and safety of intravenous tenecteplase for acute ischemic stroke (AIS) in routine clinical practice…
- Trial name
- ORIENTAL (NCT07271342)
- Testing
- tenecteplase
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Tiantan Hospital
Stroke, Ischemic
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
To date, the benefit of intravenous thrombolysis is confined within 4.5 hours of onset for acute ischemic stroke (AIS) patients without advanced neuroimaging selection.
- Trial name
- NCT06010628
- Testing
- Tenecteplase
- Where
- 2 sites in China
- Volunteers
- 1,440 people
- Sponsor
- General Hospital of Shenyang Military Region
Stroke, Ischemic
Intra-arterial Tenecteplase During First Thrombectomy Attempt for Acute Stroke (BRETIS-TNK II)
A recent pilot study suggests intra-arterial tenecteplase (TNK) during the first pass of endovascular treatment (EVT) seems safe, may increase first-pass reperfusion and good outcome in acute ischemic stroke (AIS) patients with…
- Trial name
- NCT05657444
- Testing
- Tenecteplase
- Where
- China
- Volunteers
- 380 people
- Sponsor
- General Hospital of Shenyang Military Region
Stroke, Ischemic, Stroke, Acute
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset…
- Conditions
- Stroke, Ischemic, Stroke, Acute, Thrombosis, Brain, Drug Effect
- Trial name
- TNK-LVO (NCT06658197)
- Testing
- Tenecteplase, Alteplase
- Where
- China
- Volunteers
- 850 people
- Sponsor
- Xuanwu Hospital, Beijing
Acute Ischemic Stroke, Tenecteplase
Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging
The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain.
- Trial name
- UTOPIA (NCT07475949)
- Testing
- Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment
- Where
- 15 sites in China
- Volunteers
- 352 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Stroke, Acute Ischemic, Endovascular Thrombectomy
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Study Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT.
- Conditions
- Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS
- Trial name
- ACT-REACT (NCT07687056)
- Testing
- Tenecteplase or Alteplase- depending upon availability at each treating centre, Control
- Where
- 13 sites in Australia, Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke, Large Vessel Occlusion
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who…
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients
- Trial name
- TREASURE (NCT07253181)
- Testing
- Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Where
- 2 sites in China
- Volunteers
- 572 people
- Sponsor
- Xuanwu Hospital, Beijing
Heart Arrest
Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial
The general aim of this study is to compare the efficacy and safety of tenecteplase to standard treatment during cardiopulmonary resuscitation in patients suffering from out-of-hospital cardiac arrest.
- Trial name
- NCT00157261
- Testing
- tenecteplase
- Where
- 68 sites in Austria, Belgium and 7 more
- Volunteers
- 1,050 people
- Sponsor
- Boehringer Ingelheim
Stroke, Acute
Tenecteplase Treatment in Ischemic Stroke Registry
The Tenecteplase Treatment in Acute Ischemic Stroke (TETRIS) Registry is multicenter ambispective observational study of patients with acute ischemic stroke who received intravenous thrombolysis with Tenecteplase
- Trial name
- TETRIS (NCT05534360)
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Basilar Artery Occlusion, Acute Cerebrovascular Accident
Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion
To assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.
- Conditions
- Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion
- Trial name
- NCT05701956
- Testing
- Tenecteplase, Endovascular thrombectomy
- Where
- China
- Volunteers
- 330 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Nervous System Disorders, Cerebral Artery
Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion
Proximal Middle Cerebral Artery (MCA) occlusions constitute the most severe stroke. Intra-venous thrombolysis with rt-PA within the first 4,5 hours is the only proven effective treatment.
- Trial name
- DIVA (NCT02338466)
- Testing
- rt-PA, tenecteplase
- Sponsor
- University Hospital Center of Martinique
Pleural Effusion
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.
- Trial name
- NCT01580618
- Testing
- normal saline, TNK (Tenecteplase)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kaiser Permanente
Mild Disabling Acute Ischemic Stroke
Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke
Abstract Background Intravenous thrombolysis is the cornerstone of early treatment for acute ischemic stroke (AIS), but some still have a poor prognosis, especially in patients with mild disabling stroke.
- Trial name
- BENEFIT-2 (NCT07369999)
- Testing
- Combination Group, Control Group
- Where
- 15 sites in China
- Volunteers
- 1,062 people
- Sponsor
- Xiangya Hospital of Central South University
Stroke
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND
The benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess…
- Trial name
- TRACE-BEYOND (NCT06954155)
- Testing
- Tenecteplase (0.25mg/kg), Standard medical treatment
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Beijing Tiantan Hospital
Stroke
Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy
To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI < 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.
- Trial name
- RECLAIM-TNK (NCT07471282)
- Testing
- Tenecteplase (0.0938mg/kg)
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Chuansheng Zhao
Ischemic Stroke
Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China
The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical setting.
- Trial name
- TTT-AIS CHINA (NCT06078995)
- Testing
- Tenecteplase, Alteplase
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Huashan Hospital
Stroke
ACT-GLOBAL Adaptive Platform Trial for Stroke
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke.
- Trial name
- NCT06352632
- Testing
- Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase
- Where
- 2 sites in Australia, Canada
- Volunteers
- 20,000 people
- Sponsor
- The George Institute
Stroke, Acute Ischemic Stroke
Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke
The EXTEND-TNK Registry is a prospective, multicenter, observational cohort study designed to evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours after last known well in patients with…
- Trial name
- EXTEND-TNK (NCT07536165)
- Testing
- Tenecteplase
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse
Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with Metalyse® in a real life setting outside clinical…
- Trial name
- NCT02194153
- Testing
- Metalyse weight-adjusted
- Volunteers
- 351 people
- Sponsor
- Boehringer Ingelheim